Genitope Corporation (NASDAQ: GTOP) today announced the pricing of its public offering of 5,500,000 shares of its common stock at a price of $3.85 per share. Genitope Corporation has granted the underwriter an option to purchase up to an additional 825,000 shares to cover over-allotments, if any. All of such shares are being offered by Genitope Corporation.

Punk, Ziegel & Company is the underwriter in the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. This offering of shares of common stock may be made only by means of a prospectus supplement and accompanying prospectus.

Copies of the final prospectus supplement and the accompanying prospectus can be obtained by contacting: Punk, Ziegel & Company, L.P. at 520 Madison Avenue, 4th Floor, New York, NY 10022, or by telephone at 212-308-9494, or by faxing a request to 212-308-1466.

About Genitope Corporation

Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.